Jensen Anders Boisen, Machado Ursina, Renström Frida, Aczél Stefan, Folie Patrick, Biraima-Steinemann Magdalena, Bilz Stefan
Division of Endocrinology and Diabetes, Department of Internal Medicine, Cantonal Hospital of St. Gallen, Rorschacher Strasse 95, St. Gallen, 9007, Switzerland.
Division of Surgery, Cantonal Hospital of St. Gallen, Rorschacher Strasse 95, St. Gallen, 9007, Switzerland.
BMC Endocr Disord. 2025 Apr 7;25(1):93. doi: 10.1186/s12902-025-01913-4.
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in patients with weight regain after bariatric surgery remains unclear. The objective of this study was to determine the efficacy and safety of 12 months of GLP1-RA treatment in a real-world patient population with weight regain after bariatric surgery.
A single-centre retrospective observational study. Patients with post-bariatric weight regain subsequently treated with GLP1-RA were identified, and the effect on weight after 12 months of treatment was determined. Data are presented as medians (interquartile ranges) or frequencies (%), and Wilcoxon signed-rank tests and Mann-Whitney U tests were used for paired and nonpaired group comparisons, respectively.
Forty patients (80% female) were included in the analysis. Liraglutide (3.0 mg, daily subcutaneous injection, n = 22) or semaglutide (1.0 mg, weekly subcutaneous injection, n = 18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%. After 12 months of GLP1-RA treatment, a total body weight, BMI, and percentage excess body weight reduction of 10.5 (6.1, 14.7) kg, 3.7 (2.5, 5.3) kg/m, and 41.7 (22.1, 70.5)% were observed, corresponding to a loss of 99.3 (61.0, 135.4)% of the weight regained (P-value < 0.0001). The observed reduction in BMI was significantly lower with liraglutide than with semaglutide, 3.1 (2.0, 4.7) vs. 4.7 (3.7, 6.0) kg/m (P-value = 0.04). Adverse events were reported in 13 (32.5%) patients, all of which were mild and transient.
GLP1-RA therapy with liraglutide or semaglutide for 12 months is efficacious and safe for the treatment of weight regain following bariatric surgery.
Not applicable.
胰高血糖素样肽-1受体激动剂（GLP1-RAs）在减肥手术后体重反弹患者中的作用尚不清楚。本研究的目的是确定在现实世界中减肥手术后体重反弹的患者群体中，GLP1-RA治疗12个月的疗效和安全性。
一项单中心回顾性观察研究。确定减肥后体重反弹并随后接受GLP1-RA治疗的患者，并确定治疗12个月后的体重变化。数据以中位数（四分位间距）或频率（%）表示，分别使用Wilcoxon符号秩检验和Mann-Whitney U检验进行配对和非配对组比较。
40例患者（80%为女性）纳入分析。在术后74.5（51.0，108.3）个月，体重反弹14.7（10.3，19.6）%后，开始使用利拉鲁肽（3.0mg，每日皮下注射，n = 22）或司美格鲁肽（1.0mg，每周皮下注射，n = 18）。GLP1-RA治疗12个月后，观察到总体重、BMI和超重百分比分别降低了10.5（6.1，14.7）kg、3.7（2.5，5.3）kg/m和41.7（22.1，70.5）%，相当于反弹体重减轻了99.3（61.0，135.4）%（P值<0.0001）。观察到利拉鲁肽组的BMI降低显著低于司美格鲁肽组，分别为3.1（2.0，4.7）与4.7（3.7，6.0）kg/m（P值 = 0.04）。13例（32.5%）患者报告了不良事件，均为轻度且短暂的。
利拉鲁肽或司美格鲁肽的GLP1-RA治疗12个月对减肥手术后体重反弹的治疗有效且安全。
不适用。
